InsiderTrades

Form 4 for HLF HERBALIFE LTD.

Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0000950170-24-018170 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-21 2024-02-16 HLF JOHNSON MICHAEL COB, CEO, Dir F - Tax $8.07 -30.4K 1.15M -3% -$244.9K
DM 2024-02-21 2024-02-16 HLF JOHNSON MICHAEL COB, CEO, Dir A - Grant $0.00 +580.5K 1.10M +112% $0
D 2024-02-21 2024-02-16 HLF JOHNSON MICHAEL COB, CEO, Dir P - Purchase $8.07 +61.7K 603.7K +11% +$498.1K
D 2024-02-21 2024-02-16 HLF JOHNSON MICHAEL COB, CEO, Dir A - Grant $0.00 +982.8K 982.8K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-16 F D 30,351 $8.07 1,153,857 D — — (F4) Represents shares withheld to satisfy tax obligations due in connection with the vesting of RSUs previously granted to the Reporting Person on February 16, 2024.
2 Common Common Stock 2024-02-16 A A 84,839 $0.00 1,184,208 D — — (F3) Consists of RSUs fully vested at the time of grant.
3 Common Common Stock 2024-02-16 A A 495,662 $0.00 1,099,369 D — — (F2) Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2023 Stock Incentive Plan. These RSUs will vest in two installments, 50% on February 16, 2025, and 50% on the earlier of January 3, 2026, or the date on which a new non-interim Chief Executive Officer has been appointed by the Issuer's Board of Directors (the "Board"), subject to certain conditions of his service as CEO and/or member of the Board. Provided that, in no instance shall any portion of the RSU vest prior to February 16, 2025.
4 Common Common Stock 2024-02-16 P A 61,725 $8.07 603,707 D — — (F1) This transaction represents multiple open market purchases. The range of prices for such transactions is $7.84 to $8.20. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a shareholder of the Issuer, full information regarding the number of shares purchased at each price.
5 Derivative Stock Appreciation Rights 2024-02-16 A A 982,800 $0.00 982,800 D $8.07 · — to 2034-02-16 982,800 Common Stock (F5) Consists of stock appreciation rights ("SARs") granted under the Herbalife Ltd. 2023 Stock Incentive Plan. These SARs will vest in two installments, 50% on February 16, 2025, and 50% on the earlier of January 3, 2026, or the date on which a new non-interim Chief Executive Officer has been appointed by the Board, subject to certain conditions of his service as CEO and/or member of the Board. Provided that, in no instance shall any portion of the SAR vest prior to February 16, 2025.